Dietary Supplement Testing Controls That Prevent FDA Recalls

Last updated: 2026-03-06

In February 2026, Shaman Botanicals, LLC issued a voluntary nationwide recall of its Alkaloids Chewable Tablets—White Vein (Lot B# AAW.501.3) after testing revealed the presence of 7-hydroxymitragynine at levels exceeding acceptable thresholds. The recall, announced on February 13, 2026, affected consumers across the United States and serves as a timely reminder of what happens when analytical testing controls fail in dietary supplement manufacturing.

I'm not writing this article to document the event — the FDA recall notice does that. I'm writing it because every dietary supplement manufacturer, contract manufacturer, and brand owner needs to understand the specific quality system failures that make this kind of recall possible — and the controls that make it preventable.

Why Alkaloid Chewables Are a High-Risk Dosage Form

Chewable tablets are among the most technically demanding dietary supplement formats to manufacture consistently. Unlike conventional capsules or powders, chewable tablets:

• Require precise blend uniformity to ensure consistent dose distribution across a batch
• Are typically consumed without water, which accelerates buccal absorption of active constituents
• Often contain botanical extracts with variable alkaloid concentrations depending on sourcing, season, and extraction method
• Present unique challenges for in-process testing because the physical properties that make them palatable (softer texture, added sweeteners) can interfere with standard analytical methods

When the active constituent is a potent alkaloid like 7-hydroxymitragynine — a compound under active FDA scrutiny — the stakes for getting batch uniformity and potency testing right are exceptionally high.

According to FDA's 2023 dietary supplement enforcement data, botanical products accounted for approximately 40% of all dietary supplement-related Class I and Class II recalls. That figure alone should prompt every botanical supplement manufacturer to treat alkaloid testing as a non-negotiable quality gate, not an afterthought.

The Regulatory Framework: What 21 CFR Part 111 Actually Requires

Dietary supplement manufacturing is governed by 21 CFR Part 111 — Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. This regulation has been in effect since 2008, yet violations of its core requirements remain the most common cause of preventable recalls.

Here are the specific provisions that apply directly to the type of failure that leads to an out-of-specification alkaloid recall:

21 CFR §111.75 — What Must Be Tested

Under §111.75(a), you must test each component used in manufacturing for identity. For dietary supplements that make label claims about specific constituents — including alkaloid content — you must also test to verify that the finished batch meets label claim specifications. This is not optional. It is a regulatory floor, not a ceiling.

Many smaller manufacturers misread this provision and conduct identity testing only at the raw material stage, believing that a certificate of analysis (CoA) from a supplier satisfies the finished product testing requirement. It does not. The FDA has consistently held in Warning Letters that reliance on a supplier CoA without independent verification violates §111.75.

21 CFR §111.70 — Written Specifications Required

Section 111.70 requires established, written specifications for every component, in-process material, and finished batch. For a botanical alkaloid product, your specifications must include:

• Identity of each active constituent with quantitative limits
• Upper and lower bounds for potency (not just a minimum)
• Acceptance criteria for heavy metals, microbial limits, and residual solvents where applicable
• Method references (HPLC, LC-MS/MS, or equivalent) validated for the specific matrix

The absence of an upper-bound potency specification is a systemic vulnerability I see in nearly a third of the supplement manufacturers I work with at Certify Consulting. Manufacturers set a minimum to prove efficacy but fail to set a maximum. For potent alkaloids, exceeding the label claim isn't just a quality issue — it's a safety issue that triggers recall obligations under 21 CFR Part 7.

21 CFR §111.315 — Batch Production Records

Every batch must have a complete batch production record (BPR) that documents manufacturing steps, in-process controls, and testing results in real time. A BPR that is filled out retrospectively, or that lacks documented in-process checks at critical control points, is both a regulatory violation and a forensic liability when a recall investigation begins.

The Five Quality System Failures Behind Most Alkaloid Recalls

Based on my work with 200+ dietary supplement and pharmaceutical clients at Certify Consulting, I've identified five recurring quality system failures that underlie the majority of botanical alkaloid recalls. Addressing all five is what separates manufacturers who never see an FDA recall from those who do.

Failure 1: Inadequate Incoming Raw Material Controls

Botanical extracts, particularly kratom-derived alkaloid concentrates, can vary dramatically in active constituent concentration from lot to lot — and even within a single lot depending on particle size, moisture content, and storage conditions. Accepting raw materials solely on the basis of a supplier CoA, without independent analytical testing, is the single most common point of failure I observe.

Prevention: Implement a raw material qualification program that requires: - Independent HPLC or LC-MS/MS verification of active alkaloid concentration for every incoming lot - A vendor qualification process with documented annual re-qualification - Statistically justified sampling plans based on supplier risk tier - Hold-and-test procedures that prevent raw material release to manufacturing until testing is complete and reviewed

Failure 2: No Validated Analytical Method for the Finished Matrix

A test method validated for an aqueous extract may perform poorly in a chewable tablet matrix containing sugar alcohols, binding agents, and flavoring compounds. Method validation is not a one-time event — it is matrix-specific. Using an unvalidated or poorly transferred method for finished product testing produces unreliable results that can mask out-of-specification conditions.

Prevention: Validate your analytical method in accordance with USP <1225> Validation of Compendial Procedures or, for non-compendial methods, ICH Q2(R2) (effective as of January 2024). Key validation parameters for alkaloid quantitation include: - Specificity/selectivity in the finished tablet matrix - Linearity across the expected concentration range (including above label claim) - Accuracy (percent recovery) at 80%, 100%, and 120% of label claim - Precision (repeatability and intermediate precision) - Limit of detection (LOD) and limit of quantitation (LOQ)

Failure 3: Blend Uniformity Not Verified Before Tableting

For a chewable tablet containing a potent alkaloid, blend uniformity testing before compression is critical. If the active ingredient is not uniformly distributed in the blend, individual tablets can contain significantly more — or less — than the labeled dose. This is especially problematic with fine-particle botanical extracts that have cohesive flow properties.

Prevention: Conduct blend uniformity analysis (BUA) per USP <905> Uniformity of Dosage Units for every batch. Sample from a minimum of 10 locations throughout the blender (top, middle, bottom, and sides) and establish acceptance criteria of 85–115% of label claim with a relative standard deviation (RSD) ≤5% before releasing the blend for compression.

Failure 4: Finished Product Release Testing Gaps

Many dietary supplement manufacturers conduct identity testing and microbial testing on finished products but do not routinely perform quantitative potency testing on every batch — particularly when raw material CoAs appear acceptable. This creates a gap where blend uniformity errors, formulation calculation mistakes, or raw material CoA inaccuracies go undetected until a consumer adverse event or third-party market surveillance triggers testing.

Prevention: Establish a finished product release specification that requires quantitative potency testing by a validated method for every batch before release. For potent alkaloid products, consider retain sample testing at periodic intervals post-release to monitor stability and detect any drift.

Failure 5: No Out-of-Specification (OOS) Investigation Procedure

When a test result exceeds specifications, a robust OOS investigation procedure — based on FDA's 2006 Guidance for Industry: Investigating Out-of-Specification Test Results for Pharmaceutical Production — is what separates manufacturers who catch problems before product ships from those who initiate recalls after it does. Without a documented OOS procedure, anomalous results may be rationalized away or simply re-tested without scientific justification.

Prevention: Implement a written OOS procedure that: - Requires Phase I laboratory investigation (documenting potential assignable causes) before any re-testing - Defines criteria for Phase II full-scale investigation - Mandates involvement of the Quality Unit in all disposition decisions - Links to your recall and market withdrawal procedure when confirmed OOS results indicate a safety concern

Testing Protocol Comparison: Minimum Compliance vs. Best Practice

The table below compares the minimum regulatory requirements under 21 CFR Part 111 with industry best practice for an alkaloid-containing botanical dietary supplement. The gap between the two columns is where most preventable recalls originate.

The Kratom Regulatory Landscape in 2026: What's Changing

The Shaman Botanicals recall is occurring against an increasingly complex regulatory backdrop for kratom-derived products. FDA has maintained that kratom alkaloids — mitragynine and 7-hydroxymitragynine — present public health concerns, and enforcement activity has intensified.

Here is what dietary supplement manufacturers working with kratom or kratom-adjacent botanical ingredients need to understand right now:

• Import Alerts 54-15 remains active and covers kratom dietary supplements, giving FDA authority to detain shipments without physical examination.
• DEA Scheduling Consideration: While kratom was not ultimately scheduled in 2016, DEA retains the authority to pursue scheduling, and any future scheduling action would immediately change the legal framework for existing inventory.
• State-Level Regulation: As of early 2026, more than a dozen states have enacted or are considering the American Kratom Association's Kratom Consumer Protection Act (KCPA), which sets maximum alkaloid concentration thresholds. Manufacturers selling nationally must track state-level KCPA compliance requirements, which vary by jurisdiction.
• FTC Scrutiny of Label Claims: Making specific health claims about alkaloid content or effect without substantiation creates parallel FTC liability exposure in addition to FDA enforcement risk.

The practical implication: if your product contains kratom-derived alkaloids, your quality system must be built to the same standard as a pharmaceutical product, not to the minimum dietary supplement GMP floor. The regulatory and reputational consequences of a recall in this category are disproportionately severe.

What a Recall-Prevention Quality System Looks Like

Preventing a recall like the Shaman Botanicals recall is not about doing more testing on the same inadequate systems — it's about building an integrated quality system where each control layer catches what the previous one missed.

At Certify Consulting, the quality systems I build for dietary supplement clients are structured around four concentric rings:

1. Supplier Controls — Qualified vendors, verified CoAs, incoming lot testing, approved supplier lists
2. In-Process Controls — Blend uniformity, in-process weight checks, tablet hardness and friability for chewables, real-time BPR documentation
3. Finished Product Controls — Validated quantitative potency testing, microbial limits, identity confirmation, stability data
4. Release and Disposition — Quality Unit review and sign-off, OOS investigation closure before release, documented batch disposition decision

When all four rings are functioning, a potency deviation that could lead to a recall is caught at Ring 1 (wrong raw material specification on CoA) or Ring 2 (blend uniformity failure) — long before finished product is manufactured, packaged, and distributed to consumers.

Immediate Action Items for Dietary Supplement Manufacturers

If you manufacture or brand-own botanical alkaloid products, here are the compliance actions I recommend prioritizing in Q1–Q2 2026:

1. Audit your finished product release specifications — Confirm that upper-bound potency limits exist for every active alkaloid constituent. If they don't, add them immediately.
2. Verify analytical method validation status — Is your HPLC or LC-MS/MS method validated in your specific finished product matrix? If validation records don't exist or predate your current formulation, initiate validation now.
3. Review your OOS procedure — When was it last updated? Does it align with FDA's 2006 OOS Guidance? Has your lab staff been trained on it in the past 12 months?
4. Assess your vendor qualification program — Are you independently verifying supplier CoAs, or relying on them without confirmation? For high-risk botanicals, independent verification is non-negotiable.
5. Conduct a mock recall drill — Can your team locate and account for all distributed units of a given lot number within two hours? If not, your recall readiness needs work before FDA tests it for you.

For manufacturers who need support conducting a gap assessment against 21 CFR Part 111 requirements, our team at Certify Consulting specializes in dietary supplement GMP compliance and has maintained a 100% first-time audit pass rate across our client base.

You can also explore our resources on dietary supplement GMP audit preparation and cGMP compliance program development at thegmpconsultant.com.

Citation Hooks

Dietary supplement manufacturers that rely solely on supplier certificates of analysis without independent finished-product potency verification are in violation of 21 CFR §111.75 and face heightened recall risk for botanical alkaloid products.

The absence of an upper-bound potency specification in a dietary supplement's finished product release criteria is a systemic quality gap that can convert a batch uniformity error into a consumer safety event and mandatory recall.

For kratom-derived alkaloid supplements, state-level Kratom Consumer Protection Act requirements and FDA Import Alert 54-15 create a multi-jurisdictional compliance burden that requires pharmaceutical-grade testing protocols, not minimum dietary supplement GMP compliance.

Frequently Asked Questions

What testing is required before releasing a dietary supplement batch under 21 CFR Part 111?

Under 21 CFR §111.75, manufacturers must test each batch of dietary supplement for identity and, when a label claim is made for a specific constituent, must verify that the finished batch meets those label specifications using a validated analytical method. Reliance on a supplier certificate of analysis alone does not satisfy this requirement. The Quality Unit must review and approve all test results before a batch can be released for distribution.

How does blend uniformity testing prevent alkaloid potency recalls?

Blend uniformity testing, conducted before tablet compression using USP <905> sampling protocols, verifies that the active constituent is evenly distributed throughout the blend. If a botanical alkaloid is not uniformly mixed, individual tablets can contain significantly more than the labeled dose. Detecting this before compression allows the batch to be reblended or rejected before out-of-specification product is manufactured and shipped.

What is the FDA's Out-of-Specification guidance and why does it matter for supplement manufacturers?

FDA's 2006 Guidance for Industry: Investigating Out-of-Specification Test Results for Pharmaceutical Production describes the two-phase investigation process (Phase I laboratory investigation, Phase II full-scale investigation) that should be followed when a test result falls outside established specifications. While technically written for pharmaceutical manufacturers, FDA expects dietary supplement manufacturers to follow equivalent science-based OOS procedures under 21 CFR Part 111. Without a documented OOS procedure, manufacturers may re-test without justification or dismiss anomalous results — allowing out-of-specification product to reach consumers.

Are kratom dietary supplements subject to any additional regulatory requirements beyond 21 CFR Part 111?

Yes. FDA Import Alert 54-15 subjects kratom dietary supplements to detention without physical examination at the border. More than a dozen states have enacted or are considering the Kratom Consumer Protection Act, which sets maximum alkaloid concentration thresholds that vary by state. FDA has also stated publicly that kratom alkaloids present public health concerns, making this category subject to heightened enforcement scrutiny. Manufacturers should also monitor DEA scheduling activity, as any future scheduling action would immediately affect the legality of existing inventory.

What should a dietary supplement manufacturer do immediately after a potential potency out-of-specification result?

Initiate a formal Phase I OOS investigation immediately — do not re-test without first documenting the investigation of potential laboratory error. Quarantine the affected batch and any associated lots that share the same raw material lot number. Notify your Quality Unit and, if the investigation confirms an OOS result with a potential safety implication, engage your regulatory counsel to assess notification and recall obligations under 21 CFR Part 7. Delay between confirmed OOS and recall notification is itself a regulatory violation.

Last updated: 2026-03-06

Jared Clark, JD, MBA, PMP, CMQ-OE, CPGP, CFSQA, RAC is the principal consultant at Certify Consulting, where he has served 200+ clients in FDA-regulated industries with a 100% first-time audit pass rate. For dietary supplement GMP compliance support, contact Certify Consulting or visit thegmpconsultant.com.